Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

Apple

Amazon

Costco

Alphabet

NVIDIA

Study after study shows that a long-term buy-and-hold investing strategy works best. A long-term investment is generally defined as any position in a stock that is held for a year or longer.

The Top 7 “Millionaire-Maker” Long-Term Stocks for 2023

BURNABY, British Columbia--( BUSINESS WIRE )--Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (rtCGM), is pleased to announce that coverage for Dexcom G6 rtCGM System on the Non-Insured Health Benefits (NIHB) Program has been expanded to include all clients living with type 1 diabetes. This announcement expands upon coverage already in place for clients aged 2 to 19 on intensive insulin therapy, giving even more First Nations and Inuit people access to this standard of care, potentially helping them to have more control over a life-long chronic illness.

Dexcom G6 Real-Time CGM System Now Available to All Clients With Type 1 Diabetes Covered Under the Non-Insured Health Benefits Program

Starbucks

The new year is here, and with it, more opportunities to invest in wonderful companies.

2 Best Stocks to Buy in January and Hold Forever

Let's consider a combination of two strategies involving options with the goal being to collect as much premium upfront and minimizing our risk. The post As Dexcom Settles, 2 Option Strategies Collect Premium, Minimize Risk appeared first on Investor's Business Daily.

As Dexcom Settles, 2 Option Strategies Collect Premium, Minimize Risk

DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its CGM sales.

DexCom (DXCM) Announces Solid Preliminary Q4 Revenues

This company offers products that are essential to the well-being of its customers.

1 Top Growth Stock That Could Beat the Market In 2023 and Beyond

SAN DIEGO--( BUSINESS WIRE )--DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2022 to be at least $815 million, an increase of 17% over the fourth quarter of 2021 on a reported basis and 20% on an organic1 basis. U.S. revenue is expected to be approximately $606 million, representing growth of 17% over the fourth quarter of 2021. International revenue is expected to be approximately $209 million, an increase of 15% over the fourth quarter of 2021 on a reported basis and 26% on an organic1 basis.

Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 Outlook

SAN DIEGO--( BUSINESS WIRE )--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the appointment of Teri Lawver to the newly created role of chief commercial officer. In this role, Ms. Lawver will oversee the global commercial organization with responsibility for global sales, marketing and customer experience.

Dexcom Appoints Teri Lawver as Chief Commercial Officer

Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.

3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio (Revised)

SAN DIEGO--( BUSINESS WIRE )--DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 41st annual J.P. Morgan Healthcare Conference on January 9, 2023.

Dexcom to Present at 41st Annual J.P. Morgan Healthcare Conference

Palantir Technologies

Stocks with long-term growth potential abound even in the current market.

Have $2,000 to Invest? 2 Top Stocks That Could Go Parabolic

Albemarle

Biogen

Dollar General

Enphase Energy

Etsy

First Solar

Halliburton

Organon & Co

SolarEdge Technologies

Most S&P 500 investors lost nearly 20% this year. But plenty of moneymaking stocks jumped higher.

12 Stocks Turned $10,000 To $277,126 In 12 Months

Ulta Beauty

Opportunities are abundant right now, even if share prices are down.

2 Growth Stocks to Invest $1,500 in Before the End of 2022

Amgen

Baker Hughes Co

Estee Lauder

Okta

Progressive

R1 RCM Inc

SVB Financial Group

All the companies that we follow here at 24/7 Wall St. keep a curated list for their institutional and high net worth retail clients of their highest conviction stock picks.

Jefferies Makes Massive 2023 Changes to ‘Strong Buy' Franchise List of Top Stock Picks

Dexcom is relying on the interest and sales of its new continuous glucose monitor--which recently received FDA approval--to boost revenue (and stock value).

Can FDA Approval Bolster DexCom, Inc.?

TORONTO--( BUSINESS WIRE )--Dexcom, Inc. (NASDAQ: DXCM), a leader in real-time continuous glucose monitoring (rtCGM), announced today its partnership with Green Shield and The Health Depot digital pharmacy to provide Green Shield plan members with convenient access to the Dexcom G6 rtCGM System combined with virtual diabetes coaching support.

Dexcom Canada Partners With Green Shield and The Health Depot to Offer Plan Members a Comprehensive Digital Diabetes Care Experience

One of our favorite CGM systems is getting an upgrade. The G7 is smaller than the G6, takes less time to warm up and comes with an improved app and alerts.

FDA Clears New Continuous Glucose Monitor From Dexcom

Procter & Gamble

A down market doesn't mean you should hit pause on adding new stocks to your portfolio.

Have $1,000? 2 Smart Stocks to Buy in a Nasdaq Bear Market

Dexcom stock jumped Thursday after the FDA cleared its next-generation continuous glucose monitor for patients with diabetes. The post Dexcom Flirts With Breakout After FDA Clears Next-Gen Diabetes Device appeared first on Investor's Business Daily.

Dexcom Flirts With Breakout After FDA Clears Next-Gen Diabetes Device

SAN DIEGO--( BUSINESS WIRE )--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the FDA has cleared the next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System for people with all Types of diabetes ages two years and older.

Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.

Advanced Micro Devices

Fortinet

Tesla

Not many S&P 500 stocks have enough oomph to jump 500% in five years. But a handful show it's more than possible.

Only 7 Stocks Could Gain 500% In Five Years (Tesla Isn't No. 1)

Inmode Ltd

SoFi Technologies

Next year could be a very important one for all three of these fast-growing businesses.

3 Supercharged Growth Stocks to Buy for 2023

BURNABY, British Columbia--( BUSINESS WIRE )--Dexcom, Inc. (NASDAQ: DXCM), - November is National Diabetes Awareness Month, time to bring attention to the prevalence and risk of diabetes within our diverse Canadian population, and to profile innovative strategies for prevention and management. In this context, Dexcom Canada is pleased to announce its participation in the Truckers' Health Adaptive Technology (T.H.A.T.) project, as a digital heath technology partner, in support of improving health and safety outcomes of professional truck drivers with the introduction of real-time, data-guided virtual care and coaching.

Truckers' Health Adaptative Technology (T.H.A.T.) Study Evaluates the Impact of Digital Virtual Models of Care on the Health and Wellbeing of Professional Truck Drivers

ABIOMED

Constellation Energy Corp

Wynn Resorts

Most S&P 500 investors got a little gain this month. But investors willing to look off the beaten path found huge gains.

Eleven Stocks Turned $10,000 To $261,421 In 11 Months

BeiGene

Bio-Rad Laboratories

Catalent

Edwards Lifesciences

Gilead Sciences

Intuitive Surgical

Moderna

Seagen

West Pharmaceutical Services

The healthcare sector has gained momentum following the COVID-19 pandemic. Several companies gained early regulatory approval for developing COVID-19 drugs and distributing vaccines.

News for DexCom Stock (DXCM)